مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

52
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

19
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

English: A Review on Rubella Vaccine: Iran (1975-2019) (Review Article) (French: Un examen du vaccin contre la rubé, ole: Iran (1975-2019))

Pages

  167-192

Abstract

 English: The first Attenuated Rubella Vaccine was developed by Parkman and Meyer in 1966. Ten years later in the 1975s, the Rubella Vaccine was developed in Razi Vaccine and serum research institute )RVSRI). In 1977, the Rubella TAKAHASHI Vaccine successfully passed the clinical trial and was initially used voluntarily only in the private sector. Since 1987, the administration of Rubella as MMR (Measles/AIK-C,Rubella/TAKAHASHI,Mumps/HOSHINO) strain Vaccine has been included in the immunization program in Iran. This review article focused on the development and Production of the Rubella TAKAHASHI/HDC Vaccine in RVSRI. The herd immunity and Rubella cases were investigated in the pre-and post-Vaccine era. The effectiveness and proper coverage of the Rubella Vaccine led to the elimination of Rubella from Iran in 2019. The current study aimed to assess local Rubella Vaccine manufacturing and its consequences on Rubella elimination from Iran, using various search engines. A complete search was carried out in medical databases, including PubMed, Scopus, Web of Science, Scientific Information Database, IranMedex, Magiran, and Google Scholar. Within 1972-1975, Rubella TAKAHASHI/HDC Vaccine was developed by RVSRI and successfully passed clinical trial in 1977. Over the four last decades (1980-2020), more than 40 million infants, young, and adults were vaccinated by million doses of local Rubella, measles-Rubella (MR) or measles-mumps-Rubella (MMR) Vaccine in Iran. In 1972, the pre-Vaccine era, the overall sensitivity to Rubella infection was 69% in one-year-old Iranian children and 23% in childbearing women. The use of a safe, inexpensive, and effective Vaccine increased herd immunity to 95% (85%-99%) in our country. During the last two decades, we have witnessed a 91% decline in the confirmed Rubella cases, from 1124 in 2000 to 33 cases in 2018. The current article presented the process of Vaccine development, tracked it through more than four decades, and discussed disease status before and after the Rubella Vaccine era, as well as the history of its elimination from Iran. The effectiveness of the local Razi Rubella Vaccine resulted in a significant increase in seroprevalence in Iran. Expanded vaccination against Rubella, usually with measles, has led to the elimination of Rubella from Iran as confirmed by World Health Organization in 2019. (French: Le premier vaccin atté, nué,contre la rubé, ole a é, té,mis au point par Parkman et Meyer en 1966. Dix ans plus tard, dans les anné, es 1975, le vaccin contre la rubé, ole a é, té,dé, veloppé,dans l'Institut de recherche sur les vaccins et les sé, rums de Razi (RVSRI). En 1977, le vaccin antirubé, oleux TAKAHASHI a passé,avec succè, s l'essai clinique et n'a é, té,initialement utilisé,volontairement que par le secteur privé, . Depuis 1987, l'administration de la rubé, ole sous forme de Vaccin contre la souche RRO (rougeole/AIK-C,Rubé, ole/TAKAHASHI,Oreillons/HOSHINO) a é, té,incluse dans le programme de vaccination en Iran. Cet article de synthè, se portait sur le dé, veloppement et la Production du vaccin contre la rubé, ole TAKAHASHI/HDC dans la RVSRI. Les cas d'immunité,collective et de rubé, ole ont é, té,é, tudié, s avant et aprè, s la vaccination. L'efficacité,et la couverture adé, quate du vaccin contre la rubé, ole ont conduit à,l'é, limination de la rubé, ole d'Iran en 2019. L'é, tude actuelle visait à,é, valuer la fabrication locale du vaccin contre la rubé, ole et ses consé, quences sur l'é, limination de la rubé, ole en Iran, à,l'aide de divers moteurs de recherche. Une recherche complè, te a é, té,effectué, e dans des bases de donné, es mé, dicales, notamment PubMed, Scopus, Web of Science, Scientific Information Database, IranMedex, Magiran et Google Scholar. Entre 1972 et 1975, le vaccin contre la rubé, ole TAKAHASHI/HDC a é, té,dé, veloppé,par la RVSRI et a passé,avec succè, s un essai clinique en 1977. Au cours des quatre derniè, res dé, cennies (1980-2020), plus de 40 millions de nourrissons, jeunes et adultes ont é, té,vacciné, s par des millions de doses de Vaccin contre la rubé, ole, la rougeole-rubé, ole (RR) ou la rougeole-oreillons-rubé, ole (ROR) en Iran. En 1972, à,l'é, poque pré,-vaccinale, la sensibilité,globale à,l'infection à,la rubé, ole é, tait de 69% chez les enfants iraniens d'un an et de 23% chez les femmes enceintes. L'utilisation d'un vaccin sû, r, peu coû, teux et efficace a augmenté,l'immunité,du troupeau à,95% (85%-99%) dans notre pays. Au cours des deux derniè, res dé, cennies, nous avons assisté,à,une baisse de 91% des cas confirmé, s de rubé, ole, passant de 1124 en 2000 à,33 en 2018. L'article actuel pré, sentait le processus de dé, veloppement du vaccin, le suivait pendant plus de quatre dé, cennies et discutait de l'é, tat de la maladie avant et aprè, s l'è, re de la vaccination contre la rubé, ole, ainsi que l'histoire de son é, limination d'Iran. L'efficacité,du vaccin local de la rubé, ole de Razi a entraî, né,une augmentation significative de la sé, ropré, valence en Iran. La vaccination é, tendue contre la rubé, ole, gé, né, ralement avec la rougeole, a conduit à,l'é, limination de la rubé, ole d'Iran, comme l'a confirmé,l'Organisation mondiale de la santé,(OMS) en 2019. )

Multimedia

  • No record.

    • Cites

  • No record.

    • References

  • No record.

    • Cite

    APA: Copy

    Shafayi, A., & MOHAMMADI, A.. (2021). English: A Review on Rubella Vaccine: Iran (1975-2019) (Review Article) (French: Un examen du vaccin contre la rubé, ole: Iran (1975-2019)). ARCHIVES OF RAZI INSTITUTE, 76(2), 167-192. SID. https://sid.ir/paper/1055772/en

    Vancouver: Copy

    Shafayi A., MOHAMMADI A.. English: A Review on Rubella Vaccine: Iran (1975-2019) (Review Article) (French: Un examen du vaccin contre la rubé, ole: Iran (1975-2019)). ARCHIVES OF RAZI INSTITUTE[Internet]. 2021;76(2):167-192. Available from: https://sid.ir/paper/1055772/en

    IEEE: Copy

    A. Shafayi, and A. MOHAMMADI, “English: A Review on Rubella Vaccine: Iran (1975-2019) (Review Article) (French: Un examen du vaccin contre la rubé, ole: Iran (1975-2019)),” ARCHIVES OF RAZI INSTITUTE, vol. 76, no. 2, pp. 167–192, 2021, [Online]. Available: https://sid.ir/paper/1055772/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops

  • No record.





    • Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button